Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | ACHE | P22303 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | HDAC8 | Q9BY41 | 3/20 | 0.44 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.44 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.44 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.44 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.44 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.44 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.44 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.44 |
| ▸ | HDAC9 | Q9UKV0 | 2/20 | 0.44 |
| ▸ | HDAC5 | Q9UQL6 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4119825 | 0.81 | MAPT (0.55) | KMT2AMEN1 | |
| SCHEMBL17493276 | 0.80 | MAPT (0.50) | KMT2AMEN1LMNAALDH1A1TDP1 | |
| SCHEMBL17743343 | 0.79 | TDP1 (0.49) | KMT2AMEN1TDP1 | |
| SCHEMBL12903756 | 0.78 | HPGD (0.51) | KMT2ALMNAALDH1A1TDP1MAPK1 | |
| SCHEMBL11754615 | 0.78 | ALDH1A1 (0.62) | KMT2AHSD17B10MEN1LMNAALDH1A1 | |
| SCHEMBL752241 | 0.77 | MMP2 (0.43) | KMT2AHSD17B10MEN1ALDH1A1TDP1 | |
| SCHEMBL13447825 | 0.74 | ALDH1A1 (0.55) | KMT2AHSD17B10MEN1LMNAALDH1A1 | |
| SCHEMBL18419336 | 0.74 | DUT (0.47) | KMT2ALMNAALDH1A1TDP1MAPK1 | |
| SCHEMBL31054770 | 0.74 | ALDH1A1 (0.41) | KMT2AMEN1ALDH1A1 | |
| SCHEMBL21743929 | 0.73 | BTN3A1 (0.41) | HSD17B10ALDH1A1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1914233-B1 | Silyl-protected hydroxymethyl-carbamoylalkyl-ketones as intermediates in the preparation of dopamine-beta-hydroxylase inhibitors | PORTELA & CA SA (PT) | 2011-03-02 | — | — | EP | claimed |
| EP-1914233-A1 | Peripherally-selective inhibitors of dopamine-b-hydroxylase and method of their preparation | Portela & Ca., S.A. (PT) | 2008-04-23 | — | — | EP | claimed |
| US-7259271-B2 | Peripherally-selective inhibitors of dopamine-β-hydroxylase and method of their preparation | PORTELA & C.A., S.A. (PT) | 2007-08-21 | — | — | US | claimed |
| EP-1908759-B1 | 3,4-dihydro-3-amino-2H-1-benzopyrane and -benzothiopyrane derivatives as dopamine-beta-hydroxylase Inhibitors and methods of their preparation | BIAL PORTELA & CA SA (PT) | 2012-03-21 | — | — | EP | disclosed |
| EP-1908760-B1 | Chromane and thiochromane-3-yl-1,3-dihydroimidazoles as inhibitors of dopamine-beta-hydroxylase and methods of their preparation | BIAL PORTELA & CA SA (PT) | 2011-04-13 | — | — | EP | disclosed |
| EP-1911757-B1 | Method of preparation of 3-(1,3-Dihydroimidazole-2-thione-1-yl)-chromanes and thiochromanes as dopamine-beta-hydroxylase inhibitors | PORTELA & CA SA (PT) | 2011-03-02 | — | — | EP | disclosed |
| EP-1914233-B1 | Silyl-protected hydroxymethyl-carbamoylalkyl-ketones as intermediates in the preparation of dopamine-beta-hydroxylase inhibitors | PORTELA & CA SA (PT) | 2011-03-02 | — | — | EP | disclosed |
| US-20100286219-A1 | 1, 3-Dihydroimidazoles for Treating Cardiovascular Disorders | BIAL - PORTELA & CA S.A. (PT) | 2010-11-11 | — | — | US | disclosed |
| EP-2111262-A2 | 1,3-DIHYDROIMIDAZOLES FOR TREATING CARDIOVASCULAR DISORDERS | BIAL - Portela & Ca., S.A. (PT) | 2009-10-28 | — | — | EP | disclosed |
| EP-1408038-B1 | Imidazole deriviatives and their use as peripherally-selective inhibitors of dopamine-beta-hydroxylase | BIAL PORTELA & CA SA (PT) | 2008-08-06 | — | — | EP | disclosed |
| WO-2008085074-A2 | 1, 3-DIHYDROIMIDAZOLES FOR TREATING CARDIOVASCULAR DISORDERS | BIAL-PORTELA & CA., S.A. (PT) | 2008-07-17 | — | — | WO | disclosed |
| EP-1911757-A2 | Method of preparation of 3-(1,3-Dihydroimidazole-2-thione-1-yl)-chromanes and thiochromanes as dopamine-beta-hydroxylase inhibitors | Portela & Ca., S.A. (PT) | 2008-04-16 | — | — | EP | disclosed |
| EP-1908760-A1 | Chromane and thiochromane-3-yl-1,3-dihydroimidazoles as inhibitors of dopamine-beta-hydroxylase and methods of their preparation | Portela & Ca., S.A. (PT) | 2008-04-09 | — | — | EP | disclosed |
| EP-1908759-A2 | 3,4-dihydro-3-amino-2H-1-benzopyrane and -benzothiopyrane derivatives as dopamine-beta-hydroxylase Inhibitors and methods of their preparation | Portela & Ca., S.A. (PT) | 2008-04-09 | — | — | EP | disclosed |
| US-7259271-B2 | Peripherally-selective inhibitors of dopamine-β-hydroxylase and method of their preparation | PORTELA & C.A., S.A. (PT) | 2007-08-21 | — | — | US | disclosed |
| US-20070015730-A1 | Peripherally-Selective Inhibitors of Dopamine-ß-Hydroxylase And Method Of Their Preparation | PORTELA & C.A., S.A. (PT) | 2007-01-18 | — | — | US | disclosed |
| US-7125904-B2 | Peripherally-selective inhibitors of dopamine-β-hydroxylase and method of their preparation | PORTELA & C.A., S.A. (PT) | 2006-10-24 | — | — | US | disclosed |
| US-20040142996-A1 | Peripherally-selective inhibitors of dopamine-beta-hydroxylase and method of their preparation | PORTELA & C.A., S.A. (PT) | 2004-07-22 | — | — | US | disclosed |
| WO-2004033447-A1 | IMIDAZOLE DERIVATIVES AND THEIR USE AS PERIPHERALLY-SELECTIVE INHIBITORS OF DOPAMINE-BETA-HYDROXYLASE | PORTELA & C.A., S.A. (PT) | 2004-04-22 | — | — | WO | disclosed |
| EP-1408038-A2 | Imidazole deriviatives and their use as peripherally-selective inhibitors of dopamine-beta-hydroxylase | Portela & Ca., S.A. (PT) | 2004-04-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040142996-A1 | Peripherally-selective inhibitors of dopamine-beta-hydroxylase and method of their preparation | DBH, ADRB1, ADRB3 | KMT2A 2388/4885HSD17B10 57/4885MEN1 3669/4885 |
| US-20070015730-A1 | Peripherally-Selective Inhibitors of Dopamine-ß-Hydroxylase And Method Of Their Preparation | DBH, PAH, TH | KMT2A 744/4885HSD17B10 535/4885MEN1 3745/4885 |
| US-20100286219-A1 | 1, 3-Dihydroimidazoles for Treating Cardiovascular Disorders | HTR1F, HTR1D, ADRB3 | KMT2A 2956/4885HSD17B10 820/4885MEN1 453/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.